Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5846020 | Toxicology and Applied Pharmacology | 2015 | 10 Pages |
Abstract
In conclusion, the pasireotide and osilodrostat combination did not exacerbate changes in target organ weight or toxicity compared with either monotherapy, and had an acceptable safety profile; addition of pasireotide to the osilodrostat regimen may attenuate potential adrenal gland hyperactivation and hepatocellular hypertrophy, which are potential side effects of osilodrostat monotherapy.
Keywords
Related Topics
Life Sciences
Environmental Science
Health, Toxicology and Mutagenesis
Authors
Li Li, Kapil Vashisht, Julie Boisclair, Wenkui Li, Tsu-han Lin, Herbert A. Schmid, William Kluwe, Heidi Schoenfeld, Peter Hoffmann,